HRQoL by EORTC Quality of Life Questionnaire LC13 Score Coughing
A Study Comparing Alectinib With Crizotinib in Treatment-Naive Anaplastic Lymphoma Kinase-Positive Advanced Non-Small Cell Lung Cancer Participants · Source last updated 2026-05-29
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
Measure
MEDIAN
Unit
Score on a scale
Interval / dispersion
Full Range
Time frame
Baseline, every 4 weeks until disease progression (up to 33 months)
What was measured
The EORTC QLQ-LC13 module generated one multiple-item scale score assessing dyspnea and a series of single item scores assessing chest pain, arm/shoulder pain, pain in other parts, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis. All the scales and single-item scores were linearly transformed so that each score ranged from 0 to 100. A higher score on the global health and functioning subscales is indicative of better functioning.
Analysis population: ITT population included all participants randomized in the study, irrespective of whether or not they received study drug. Number analyzed indicates number of participants evaluated for specified time points.
Groups in this outcome
Alectinib
Participants received alectinib at 600 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.
Crizotinib
Participants received crizotinib at 250 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.
Group identifiers and denominators belong to this outcome only. They may differ in another outcome or in safety reporting.
Analysis denominator · Participants
Group
Source count
Alectinib
152
Crizotinib
151
Reported measurements
Baseline
Analysis denominator · Participants
Group
Source count
Alectinib
100
Crizotinib
96
Values in Score on a scale · Interval/dispersion: Full Range
Group
Value
Spread
Lower
Upper
Comment
Alectinib
33.33
Not reported
0.0
100.0
Not reported
Crizotinib
33.33
Not reported
0.0
100.0
Not reported
Treatment - week 4
Analysis denominator · Participants
Group
Source count
Alectinib
95
Crizotinib
89
Values in Score on a scale · Interval/dispersion: Full Range
Group
Value
Spread
Lower
Upper
Comment
Alectinib
33.33
Not reported
0.0
100.0
Not reported
Crizotinib
33.33
Not reported
0.0
100.0
Not reported
Treatment - week 8
Analysis denominator · Participants
Group
Source count
Alectinib
89
Crizotinib
84
Values in Score on a scale · Interval/dispersion: Full Range
Group
Value
Spread
Lower
Upper
Comment
Alectinib
33.33
Not reported
0.0
66.7
Not reported
Crizotinib
33.33
Not reported
0.0
100.0
Not reported
Treatment - week 12
Analysis denominator · Participants
Group
Source count
Alectinib
75
Crizotinib
78
Values in Score on a scale · Interval/dispersion: Full Range
Group
Value
Spread
Lower
Upper
Comment
Alectinib
33.33
Not reported
0.0
100.0
Not reported
Crizotinib
0.0
Not reported
0.0
66.7
Not reported
Treatment - week 16
Analysis denominator · Participants
Group
Source count
Alectinib
79
Crizotinib
73
Values in Score on a scale · Interval/dispersion: Full Range
Group
Value
Spread
Lower
Upper
Comment
Alectinib
0.0
Not reported
0.0
100.0
Not reported
Crizotinib
0.0
Not reported
0.0
66.7
Not reported
Treatment - week 20
Analysis denominator · Participants
Group
Source count
Alectinib
73
Crizotinib
67
Values in Score on a scale · Interval/dispersion: Full Range
Group
Value
Spread
Lower
Upper
Comment
Alectinib
33.33
Not reported
0.0
100.0
Not reported
Crizotinib
0.0
Not reported
0.0
66.7
Not reported
Treatment - week 24
Analysis denominator · Participants
Group
Source count
Alectinib
77
Crizotinib
71
Values in Score on a scale · Interval/dispersion: Full Range
Group
Value
Spread
Lower
Upper
Comment
Alectinib
33.33
Not reported
0.0
100.0
Not reported
Crizotinib
33.33
Not reported
0.0
100.0
Not reported
Treatment - week 28
Analysis denominator · Participants
Group
Source count
Alectinib
67
Crizotinib
62
Values in Score on a scale · Interval/dispersion: Full Range
Group
Value
Spread
Lower
Upper
Comment
Alectinib
33.33
Not reported
0.0
100.0
Not reported
Crizotinib
16.67
Not reported
0.0
100.0
Not reported
Treatment - week 32
Analysis denominator · Participants
Group
Source count
Alectinib
73
Crizotinib
65
Values in Score on a scale · Interval/dispersion: Full Range
Group
Value
Spread
Lower
Upper
Comment
Alectinib
33.33
Not reported
0.0
100.0
Not reported
Crizotinib
33.33
Not reported
0.0
100.0
Not reported
Treatment - week 36
Analysis denominator · Participants
Group
Source count
Alectinib
64
Crizotinib
61
Values in Score on a scale · Interval/dispersion: Full Range
Group
Value
Spread
Lower
Upper
Comment
Alectinib
0.0
Not reported
0.0
100.0
Not reported
Crizotinib
0.0
Not reported
0.0
66.7
Not reported
Treatment - week 40
Analysis denominator · Participants
Group
Source count
Alectinib
74
Crizotinib
50
Values in Score on a scale · Interval/dispersion: Full Range
Group
Value
Spread
Lower
Upper
Comment
Alectinib
33.33
Not reported
0.0
66.7
Not reported
Crizotinib
0.0
Not reported
0.0
66.7
Not reported
Treatment - week 44
Analysis denominator · Participants
Group
Source count
Alectinib
62
Crizotinib
47
Values in Score on a scale · Interval/dispersion: Full Range
Group
Value
Spread
Lower
Upper
Comment
Alectinib
0.0
Not reported
0.0
66.7
Not reported
Crizotinib
0.0
Not reported
0.0
66.7
Not reported
Treatment - week 48
Analysis denominator · Participants
Group
Source count
Alectinib
67
Crizotinib
47
Values in Score on a scale · Interval/dispersion: Full Range
Group
Value
Spread
Lower
Upper
Comment
Alectinib
33.33
Not reported
0.0
66.7
Not reported
Crizotinib
0.0
Not reported
0.0
66.7
Not reported
Treatment - week 52
Analysis denominator · Participants
Group
Source count
Alectinib
58
Crizotinib
44
Values in Score on a scale · Interval/dispersion: Full Range
Group
Value
Spread
Lower
Upper
Comment
Alectinib
0.0
Not reported
0.0
66.7
Not reported
Crizotinib
0.0
Not reported
0.0
33.3
Not reported
Treatment - week 56
Analysis denominator · Participants
Group
Source count
Alectinib
61
Crizotinib
48
Values in Score on a scale · Interval/dispersion: Full Range
Group
Value
Spread
Lower
Upper
Comment
Alectinib
0.0
Not reported
0.0
66.7
Not reported
Crizotinib
0.0
Not reported
0.0
100.0
Not reported
Treatment - week 60
Analysis denominator · Participants
Group
Source count
Alectinib
47
Crizotinib
39
Values in Score on a scale · Interval/dispersion: Full Range
Group
Value
Spread
Lower
Upper
Comment
Alectinib
33.33
Not reported
0.0
100.0
Not reported
Crizotinib
0.0
Not reported
0.0
66.7
Not reported
Treatment - week 64
Analysis denominator · Participants
Group
Source count
Alectinib
55
Crizotinib
39
Values in Score on a scale · Interval/dispersion: Full Range
Group
Value
Spread
Lower
Upper
Comment
Alectinib
33.33
Not reported
0.0
66.7
Not reported
Crizotinib
0.0
Not reported
0.0
66.7
Not reported
Treatment - week 68
Analysis denominator · Participants
Group
Source count
Alectinib
49
Crizotinib
34
Values in Score on a scale · Interval/dispersion: Full Range
Group
Value
Spread
Lower
Upper
Comment
Alectinib
33.33
Not reported
0.0
66.7
Not reported
Crizotinib
0.0
Not reported
0.0
66.7
Not reported
Treatment - week 72
Analysis denominator · Participants
Group
Source count
Alectinib
54
Crizotinib
34
Values in Score on a scale · Interval/dispersion: Full Range
Group
Value
Spread
Lower
Upper
Comment
Alectinib
0.0
Not reported
0.0
66.7
Not reported
Crizotinib
0.0
Not reported
0.0
66.7
Not reported
Treatment - week 76
Analysis denominator · Participants
Group
Source count
Alectinib
42
Crizotinib
29
Values in Score on a scale · Interval/dispersion: Full Range
Group
Value
Spread
Lower
Upper
Comment
Alectinib
0.0
Not reported
0.0
66.7
Not reported
Crizotinib
0.0
Not reported
0.0
66.7
Not reported
Treatment - week 80
Analysis denominator · Participants
Group
Source count
Alectinib
43
Crizotinib
23
Values in Score on a scale · Interval/dispersion: Full Range
Group
Value
Spread
Lower
Upper
Comment
Alectinib
33.33
Not reported
0.0
66.7
Not reported
Crizotinib
0.0
Not reported
0.0
33.33
Not reported
Treatment - week 84
Analysis denominator · Participants
Group
Source count
Alectinib
33
Crizotinib
19
Values in Score on a scale · Interval/dispersion: Full Range
Group
Value
Spread
Lower
Upper
Comment
Alectinib
0.0
Not reported
0.0
66.7
Not reported
Crizotinib
0.0
Not reported
0.0
33.33
Not reported
Treatment - week 88
Analysis denominator · Participants
Group
Source count
Alectinib
36
Crizotinib
16
Values in Score on a scale · Interval/dispersion: Full Range
Group
Value
Spread
Lower
Upper
Comment
Alectinib
33.33
Not reported
0.0
100.0
Not reported
Crizotinib
0.0
Not reported
0.0
33.33
Not reported
Treatment - week 92
Analysis denominator · Participants
Group
Source count
Alectinib
30
Crizotinib
13
Values in Score on a scale · Interval/dispersion: Full Range
Group
Value
Spread
Lower
Upper
Comment
Alectinib
0.0
Not reported
0.0
66.7
Not reported
Crizotinib
0.0
Not reported
0.0
66.7
Not reported
Treatment - week 96
Analysis denominator · Participants
Group
Source count
Alectinib
22
Crizotinib
11
Values in Score on a scale · Interval/dispersion: Full Range
Group
Value
Spread
Lower
Upper
Comment
Alectinib
16.67
Not reported
0.0
66.7
Not reported
Crizotinib
0.0
Not reported
0.0
33.33
Not reported
Treatment - week 100
Analysis denominator · Participants
Group
Source count
Alectinib
18
Crizotinib
10
Values in Score on a scale · Interval/dispersion: Full Range
Group
Value
Spread
Lower
Upper
Comment
Alectinib
0.0
Not reported
0.0
100.0
Not reported
Crizotinib
0.0
Not reported
0.0
33.3
Not reported
Treatment - week 104
Analysis denominator · Participants
Group
Source count
Alectinib
15
Crizotinib
7
Values in Score on a scale · Interval/dispersion: Full Range
Group
Value
Spread
Lower
Upper
Comment
Alectinib
33.33
Not reported
0.0
66.7
Not reported
Crizotinib
0.0
Not reported
0.0
33.3
Not reported
Treatment - week 108
Analysis denominator · Participants
Group
Source count
Alectinib
11
Crizotinib
7
Values in Score on a scale · Interval/dispersion: Full Range
Group
Value
Spread
Lower
Upper
Comment
Alectinib
33.33
Not reported
0.0
66.7
Not reported
Crizotinib
33.33
Not reported
0.0
33.33
Not reported
Treatment - week 112
Analysis denominator · Participants
Group
Source count
Alectinib
9
Crizotinib
4
Values in Score on a scale · Interval/dispersion: Full Range
Group
Value
Spread
Lower
Upper
Comment
Alectinib
33.33
Not reported
0.0
33.33
Not reported
Crizotinib
0.0
Not reported
0.0
33.33
Not reported
Treatment - week 116
Analysis denominator · Participants
Group
Source count
Alectinib
4
Crizotinib
2
Values in Score on a scale · Interval/dispersion: Full Range
Group
Value
Spread
Lower
Upper
Comment
Alectinib
33.33
Not reported
0.0
33.33
Not reported
Crizotinib
16.67
Not reported
0.0
33.33
Not reported
Treatment - week 120
Analysis denominator · Participants
Group
Source count
Alectinib
3
Crizotinib
0
Values in Score on a scale · Interval/dispersion: Full Range
Group
Value
Spread
Lower
Upper
Comment
Alectinib
33.33
Not reported
33.33
33.33
Not reported
Complete source fields
classes
categories
measurements
group Id
OG000
lower Limit
0.0
upper Limit
100.0
value
33.33
group Id
OG001
lower Limit
0.0
upper Limit
100.0
value
33.33
denoms
counts
group Id
OG000
value
100
group Id
OG001
value
96
units
Participants
title
Baseline
categories
measurements
group Id
OG000
lower Limit
0.0
upper Limit
100.0
value
33.33
group Id
OG001
lower Limit
0.0
upper Limit
100.0
value
33.33
denoms
counts
group Id
OG000
value
95
group Id
OG001
value
89
units
Participants
title
Treatment - week 4
categories
measurements
group Id
OG000
lower Limit
0.0
upper Limit
66.7
value
33.33
group Id
OG001
lower Limit
0.0
upper Limit
100.0
value
33.33
denoms
counts
group Id
OG000
value
89
group Id
OG001
value
84
units
Participants
title
Treatment - week 8
categories
measurements
group Id
OG000
lower Limit
0.0
upper Limit
100.0
value
33.33
group Id
OG001
lower Limit
0.0
upper Limit
66.7
value
0.0
denoms
counts
group Id
OG000
value
75
group Id
OG001
value
78
units
Participants
title
Treatment - week 12
categories
measurements
group Id
OG000
lower Limit
0.0
upper Limit
100.0
value
0.0
group Id
OG001
lower Limit
0.0
upper Limit
66.7
value
0.0
denoms
counts
group Id
OG000
value
79
group Id
OG001
value
73
units
Participants
title
Treatment - week 16
categories
measurements
group Id
OG000
lower Limit
0.0
upper Limit
100.0
value
33.33
group Id
OG001
lower Limit
0.0
upper Limit
66.7
value
0.0
denoms
counts
group Id
OG000
value
73
group Id
OG001
value
67
units
Participants
title
Treatment - week 20
categories
measurements
group Id
OG000
lower Limit
0.0
upper Limit
100.0
value
33.33
group Id
OG001
lower Limit
0.0
upper Limit
100.0
value
33.33
denoms
counts
group Id
OG000
value
77
group Id
OG001
value
71
units
Participants
title
Treatment - week 24
categories
measurements
group Id
OG000
lower Limit
0.0
upper Limit
100.0
value
33.33
group Id
OG001
lower Limit
0.0
upper Limit
100.0
value
16.67
denoms
counts
group Id
OG000
value
67
group Id
OG001
value
62
units
Participants
title
Treatment - week 28
categories
measurements
group Id
OG000
lower Limit
0.0
upper Limit
100.0
value
33.33
group Id
OG001
lower Limit
0.0
upper Limit
100.0
value
33.33
denoms
counts
group Id
OG000
value
73
group Id
OG001
value
65
units
Participants
title
Treatment - week 32
categories
measurements
group Id
OG000
lower Limit
0.0
upper Limit
100.0
value
0.0
group Id
OG001
lower Limit
0.0
upper Limit
66.7
value
0.0
denoms
counts
group Id
OG000
value
64
group Id
OG001
value
61
units
Participants
title
Treatment - week 36
categories
measurements
group Id
OG000
lower Limit
0.0
upper Limit
66.7
value
33.33
group Id
OG001
lower Limit
0.0
upper Limit
66.7
value
0.0
denoms
counts
group Id
OG000
value
74
group Id
OG001
value
50
units
Participants
title
Treatment - week 40
categories
measurements
group Id
OG000
lower Limit
0.0
upper Limit
66.7
value
0.0
group Id
OG001
lower Limit
0.0
upper Limit
66.7
value
0.0
denoms
counts
group Id
OG000
value
62
group Id
OG001
value
47
units
Participants
title
Treatment - week 44
denoms
counts
group Id
OG000
value
152
group Id
OG001
value
151
units
Participants
description
The EORTC QLQ-LC13 module generated one multiple-item scale score assessing dyspnea and a series of single item scores assessing chest pain, arm/shoulder pain, pain in other parts, coughing, sore mouth, dysphagia, peripheral neuropathy, alopecia, and hemoptysis. All the scales and single-item scores were linearly transformed so that each score ranged from 0 to 100. A higher score on the global health and functioning subscales is indicative of better functioning.
dispersion Type
Full Range
groups
description
Participants received alectinib at 600 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.
id
OG000
title
Alectinib
description
Participants received crizotinib at 250 mg orally BID from Visit 0 (baseline) until disease progression, unacceptable toxicity, withdrawal of consent or death.
id
OG001
title
Crizotinib
param Type
MEDIAN
population Description
ITT population included all participants randomized in the study, irrespective of whether or not they received study drug. Number analyzed indicates number of participants evaluated for specified time points.
reporting Status
POSTED
time Frame
Baseline, every 4 weeks until disease progression (up to 33 months)
title
HRQoL by EORTC Quality of Life Questionnaire LC13 Score Coughing
Triangle